相关实验视频

Updated: Mar 1, 2026

Isolation, Enrichment, and Maintenance of Medulloblastoma Stem Cells

Isolation, Enrichment, and Maintenance of Medulloblastoma Stem Cells

Published on: September 1, 2010

CSNK1E在扩散型大B细胞淋巴瘤中维持类似干细胞的药物持久性

Xiang Li¹, Mengke Liu², Qing Shi³

¹Shanghai Institute of Hematology, State Key Laboratory of Medical Genomics, National Research Center for Translational Medicine at Shanghai, Ruijin Hospital Affiliated to Shanghai Jiao Tong Universi, Shanghai, China.

|February 27, 2026

概括

扩散性大B细胞淋巴瘤 (DLBCL) 中的耐药细胞采用类似干细胞的特性,驱动治疗耐药性. 向CSNK1E提供了一种克服这种耐药性的新策略,并提高标准免疫化学疗法的疗效.

科学领域:

血液学血液学血液学
在瘤学瘤学.
分子生物学分子生物学

背景情况:

复发性或耐药性 (R/R) 疾病在免疫化疗后影响高达40%的扩散性大B细胞淋巴瘤 (DLBCL) 患者.
在DLBCL中药物持续性的分子机制尚未完全理解.

研究的目的:

研究DLBCL中耐药细胞的分子和功能特征.
确定潜在的治疗点,以克服DLBCL的治疗阻力.

主要方法:

在对联诊断和R/R DLBCL样本上对单细胞RNA和B细胞受体进行测序.
在三个独立的患者队列中进行验证.
在体外和体外功能测定和机械学研究.

主要成果:

药物耐药DLBCL细胞表现出较少差异化的,类似干细胞的表型,具有B细胞记忆特征.
这些类似干细胞表现出增加的克隆原性和瘤发起能力,与糟糕的结果相关.
由APRIL-TNFRSF13B轴驱动的CSNK1E的升调在类似干细胞中被确定.
抑制CSNK1E减少了瘤生长,并提高了R-CHOP治疗的疗效.

结论:

耐药DLBCL细胞具有类似干细胞的特性,导致治疗失败.
CSNK1E是药物持续性的关键媒介,也是潜在的治疗标.
向CSNK1E可能会改善R/R DLBCL患者的治疗结果,这些患者接受标准免疫化学疗法.

更多相关视频

Methods for Evaluating the Role of c-Fos and Dusp1 in Oncogene Dependence

Methods for Evaluating the Role of c-Fos and Dusp1 in Oncogene Dependence

Published on: January 7, 2019

Through the Looking Glass: Time-lapse Microscopy and Longitudinal Tracking of Single Cells to Study Anti-cancer Therapeutics

Through the Looking Glass: Time-lapse Microscopy and Longitudinal Tracking of Single Cells to Study Anti-cancer Therapeutics

Published on: May 14, 2016

相关概念视频

Cancer Stem Cells and Tumor Maintenance

Cancer Stem Cells and Tumor Maintenance

Early diagnosis and treatment can often cure cancer. However, even with treatment, residual cells called cancer stem cells (CSC) might remain, often causing tumor recurrence. These cancer stem cells possess the potential for self-renewal and multi-lineage differentiation and are often responsible for the therapeutic resistance displayed in most cancers.
Cancer stem cells are thought to originate from tissue-specific normal stem cells or progenitor cells. The normal stem cells usually reside in...

Multipotency of Hematopoietic Stem Cells

Multipotency of Hematopoietic Stem Cells

The hematopoietic stem cells or HSCs are multipotent, meaning they can differentiate and give rise to all blood and immune cells. HSCs are maintained in the quiescent stage until an external stimulus initiates their differentiation. The multipotent HSCs exist as two heterogeneous populations, long-term repopulating cells (LTRC) and short-term repopulating cells (STRC). The two HSC populations have different surface markers or receptors and are classified based on quiescence and long-term...